A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 11, 2012, Pages 1000-1009

  Chou, H S ^a   Truitt, K E ^a   Moberly, J B ^a   Merante, D ^b   Choi, Y ^a   Mun, Y ^a   Pfutzner A ^c  

^a DAIICHI SANKYO INC   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c IKFE Institute for Clinical Research and Development   (Germany)

Author keywords

Glycaemic control; Monotherapy; Pioglitazone; Rivoglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIVOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PITTING EDEMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUICIDE ATTEMPT; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; WEIGHT GAIN;

EID: 84867140576     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01631.x     Document Type: Article

References (46)

1. Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract 2008; 14: 625-638.
2. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
5. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl. 1): 1-68.
6. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl. 1): S11-S61.
7. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008; 18: 222-229.
8. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
9. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 2007; 120: S18-S25.
10. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
11. Hanefeld M, Marx N, Pfützner A et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297.
12. Langenfeld MR, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
13. Forst T, Lübben G, Hohberg C et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005; 12: 543-550.
14. Pfützner A, Marx N, Lübben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
15. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.
16. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136.
17. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108: 2941-2948.
18. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
19. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
20. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
22. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342: d1309.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
24. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
25. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
26. U.S. Food and Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. 2011. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed 3 January 2012.
27. European Medicines Agency. Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact). 2011. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109179.pdf. Accessed 9 February 2012.
28. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169: 1395-1402.
29. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
30. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.
31. Truitt KE, Goldberg RB, Rosenstock J et al. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin 2010; 26: 1321-1331.
32. Rohatagi S, Carrothers TJ, Jin J et al. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol 2008; 48: 1420-1429.
33. Dmitrienko A, Wiens BL, Tamhane AC, Wang X. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med 2007; 26: 2465-2478.
34. Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007; 11: 507-524vi.
35. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008; 10: 1204-1211.
36. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.
37. Pfützner A, Hohberg C, Lübben G et al. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005; 37: 510-515.
38. Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-2464.
39. Leonhardt W, Pfützner A, Müller J et al. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis 2008; 201: 155-162.
40. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
41. Deeks ED, Keam SJ. Rosiglitazone : a review of its use in type 2 diabetes mellitus. Drugs 2007; 67: 2747-2779.
42. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006; 66: 85-109.
43. European Medicines Agency. Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). 2010. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/09/WC500097003.pdf. Accessed 27 October 2011.
44. U.S. Food and Drug Administration. Avandia (rosiglitazone): REMS - Risk of Cardiovascular Events. 2011. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm. Accessed 27 October 2011.
45. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
46. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.